Table 3.
Results of intratumoral phosphorus-32 microbrachytherapy for locally advanced pancreatic cancer
| Reference | n | Metastasis | Type of 32P therapy | Tumour dose (Gy), median* (range) | Combination therapy | Overall complications, n | Complications ≥grade III | Median* survival (months); OS initiation | NOS 1–9 |
|---|---|---|---|---|---|---|---|---|---|
| Percutaneous | |||||||||
| Order et al., 199659 | 47 | 19 (40) | MAA and colloidal chromic 32P | (9000–17 000) | CRT 47 (100) | 27 | 10 (53) | 9.9; T | 8 |
| Rosemurgy et al., 200858 | 18 | 0 (0) | Colloidal chromic 32P | 1255 | CRT 18 (100) | NR | 16 (89) | 5.2 | 8† |
| Westlin et al., 199761 | 17 | 0 (0) | MAA and colloidal chromic 32P | 5000 (1390–19 000) | CHT 2 (12) | NR | 1 (6) | 7.6; T | 6 |
| Total percutaneous | 82 | 19 of 82 (23) | MAA and/or colloidal chromic 32P | NA | CHT 2 (2), CRT 65 (79) | 27 of 47 | 27 of 82 (33) | NA | NA |
| EUS | |||||||||
| Bhutani et al., 201960 | 9 | 0 (0) | Microparticle | 100 | CHT 9 (100) | NR | 24 (NR)‡ | NR | 4 |
| Ross et al., 202124 | 42 | 0 (0) | Microparticle | 100 | CHT 42 (100) | 1095 | 34 (81) | 15.5; Inc | 5 |
| Total EUS | 51 | 0 of 51 (0) | Microparticle | NA | CHT 51 (100) | 1095 of 42 | 34 of 42 (81) | NA | NA |
| Total | 133 | 19 of 133 (14.3) | MAA and/or colloidal chromic 32P or Microparticle | NA | CHT 53 (39.8), CRT 65 (48.9) | 1122 of 89 | 61 of 124 (49.2) | NA | NA |
Values are n (%) unless otherwise stated. *If the median was unavailable the mean is presented. †RCT. ‡n = number of complications. OS, overall survival; NOS, Newcastle–Ottawa scale; MAA, macroaggregated albumin; CRT, chemoradiotherapy; T, treatment; NR, not reported; CHT, chemotherapy; NA, not applicable; EUS, endoscopic ultrasonography; Inc, inclusion.